MedTrace Logo

Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia

NCT05838625 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 464

Last updated 2025-10-16

No results posted yet for this study

Summary

This study evaluates the efficacy of two prescription digital therapeutics (PDT) in addition to standard of care (SOC) therapy for the treatment of experiential negative symptoms of schizophrenia in late adolescents and adults.

Conditions

Interventions

DEVICE

Digital Therapeutic

A prescription digital therapeutic in the form of a smartphone app.

Sponsors & Collaborators

Principal Investigators

  • Viveca Livezey, MD · Click Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-31
Primary Completion
2025-06-20
Completion
2025-07-23
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05838625 on ClinicalTrials.gov